Difference between revisions of "Tislelizumab (Baizean)"
Jump to navigation
Jump to search
m (Jwarner moved page Tislelizumab (BGB-A317) to Tislelizumab (Baizean): brand name) |
m |
||
Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
− | |||
*[[Esophageal squamous cell carcinoma]] | *[[Esophageal squamous cell carcinoma]] | ||
*[[Hepatocellular carcinoma]] | *[[Hepatocellular carcinoma]] | ||
Line 11: | Line 10: | ||
**[[Non-small cell lung cancer, nonsquamous]] | **[[Non-small cell lung cancer, nonsquamous]] | ||
**[[Non-small cell lung cancer, squamous]] | **[[Non-small cell lung cancer, squamous]] | ||
+ | *[[Urothelial carcinoma]] | ||
+ | *[[MSI-H or dMMR|MSI-H or dMMR solid tumors (tissue-agnostic)]] | ||
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
*2019-12-26: Initial approval | *2019-12-26: Initial approval | ||
+ | *Uncertain date: Full approval for first-line treatment of patients with advanced [[Non-small cell lung cancer, squamous|squamous non-small cell lung cancer (NSCLC)]] in combination with chemotherapy. | ||
+ | *Uncertain date: Full approval for first-line treatment of patients with advanced [[Non-small cell lung cancer, nonsquamous|non-squamous NSCLC]] in combination with chemotherapy. | ||
+ | *Uncertain date: Full approval for second- or third-line treatment of patients with locally advanced or metastatic [[Non-small cell lung cancer|NSCLC]] who progressed on prior platinum-based chemotherapy. | ||
+ | *Uncertain date: Conditional approval for the treatment of patients with [[Classical Hodgkin lymphoma|classical Hodgkin’s lymphoma (cHL)]] who received at least two prior therapies | ||
+ | *Uncertain date: Conditional approval for the treatment of patients with locally advanced or metastatic [[Urothelial carcinoma|urothelial carcinoma (UC)]] with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy | ||
+ | *Uncertain date: Conditional approval for the treatment of patients with [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC)]] who have received at least one systemic therapy | ||
+ | *Uncertain date: Conditional approval for the treatment of patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) [[:Category:Malignant solid neoplasm|solid tumors]]. | ||
+ | |||
==Also known as== | ==Also known as== | ||
*'''Code name:''' BGB-A317 | *'''Code name:''' BGB-A317 | ||
Line 23: | Line 32: | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
− | |||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
[[Category:Hepatocellular carcinoma medications]] | [[Category:Hepatocellular carcinoma medications]] | ||
[[Category:Classical Hodgkin lymphoma medications]] | [[Category:Classical Hodgkin lymphoma medications]] | ||
+ | [[Category:MSI-H or dMMR medications]] | ||
[[Category:Nasopharyngeal carcinoma medications]] | [[Category:Nasopharyngeal carcinoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Non-small cell lung cancer, nonsquamous medications]] | [[Category:Non-small cell lung cancer, nonsquamous medications]] | ||
[[Category:Non-small cell lung cancer, squamous medications]] | [[Category:Non-small cell lung cancer, squamous medications]] | ||
+ | [[Category:Urothelial carcinoma medications]] | ||
+ | |||
[[Category:NMPA approved in 2019]] | [[Category:NMPA approved in 2019]] |
Revision as of 13:29, 9 September 2023
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Classical Hodgkin lymphoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer
- Urothelial carcinoma
- MSI-H or dMMR solid tumors (tissue-agnostic)
History of changes in NMPA indication
- 2019-12-26: Initial approval
- Uncertain date: Full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy.
- Uncertain date: Full approval for first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy.
- Uncertain date: Full approval for second- or third-line treatment of patients with locally advanced or metastatic NSCLC who progressed on prior platinum-based chemotherapy.
- Uncertain date: Conditional approval for the treatment of patients with classical Hodgkin’s lymphoma (cHL) who received at least two prior therapies
- Uncertain date: Conditional approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- Uncertain date: Conditional approval for the treatment of patients with hepatocellular carcinoma (HCC) who have received at least one systemic therapy
- Uncertain date: Conditional approval for the treatment of patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.
Also known as
- Code name: BGB-A317
- Generic name: tilelizumab
- Brand name: Baizean
Categories:
- Drugs
- Intravenous medications
- Anti-PD-1 antibodies
- Esophageal cancer medications
- Hepatocellular carcinoma medications
- Classical Hodgkin lymphoma medications
- MSI-H or dMMR medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- Urothelial carcinoma medications
- NMPA approved in 2019